Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 4 1Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

EGFR-Mutant Lung Cancer 1

Interventions

Paclitaxel 292Gemcitabine 254Carboplatin 254Cisplatin 251Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 181Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Pemetrexed 90Ipilimumab 90fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Completed × Lead × Clear all
NCT01967095 2018-11-13

Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
53 enrolled
Thoracic

EGFR-Mutant Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡